Synthesis and Preclinical Evaluation of Radiolabeled [(103)Ru]BOLD-100

The first-in-class ruthenium-based chemotherapeutic agent BOLD-100 (formerly IT-139, NKP-1339, KP1339) is currently the subject of clinical evaluation for the treatment of gastric, pancreatic, colorectal and bile duct cancer. A radiolabeled version of the compound could present a helpful diagnostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Happl, Barbara, Brandt, Marie, Balber, Theresa, Benčurová, Katarína, Talip, Zeynep, Voegele, Alexander, Heffeter, Petra, Kandioller, Wolfgang, Van der Meulen, Nicholas P., Mitterhauser, Markus, Hacker, Marcus, Keppler, Bernhard K., Mindt, Thomas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674160/
https://www.ncbi.nlm.nih.gov/pubmed/38004604
http://dx.doi.org/10.3390/pharmaceutics15112626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674160/
https://www.ncbi.nlm.nih.gov/pubmed/38004604
http://dx.doi.org/10.3390/pharmaceutics15112626

Ejemplares similares